GS-9620 alleviates psoriasis-like inflammation by regulating autophagy in keratinocytes
Yansi Lyu , Wei Zhou , Pei Zhang , Chen Lin , Xin Wen , Zigang Zhao , Guoqiang Zhang , Qian Zhang , Si Chen
Animal Models and Experimental Medicine ›› 2026, Vol. 9 ›› Issue (7) : 1364 -1372.
Background: Psoriasis is an immune-driven dermatosis marked by keratinocyte hyperproliferation. GS-9620, a TLR7 agonist, previously mitigated EV71-triggered inflammation in mice; here we probe its anti-psoriatic potential and mechanisms.
Methods: IMQ-induced psoriasis-like mice were treated with GS-9620 or MTX; severity was tracked by PASI and histology. Skin/spleen cytokines (IL-1β, IL-6, IL-18, HMGB1, TNF-α) were quantified via ELISA; immune subsets were quantified by flow cytometry. Autophagy proteins (ATG5/12/16 L1) and NLRP3 were assessed by IHC/Western blot. In vitro, M5-stimulated primary keratinocytes were treated with GS-9620 ± autophagy modulators, followed by cytokine and protein analyses.
Results: GS-9620 markedly reduced erythema, scaling and epidermal thickness, lowered skin and systemic cytokines, and decreased splenic CD3+/CD4+IL-17A+ cells. It restored ATG5/12/16 L1 expression while suppressing NLRP3 both in lesions and in M5-stimulated keratinocytes, leading to diminished IL-1β, IL-6, IL-18, HMGB1 and TNF-α release.
Conclusions: GS-9620 alleviates psoriasis by enhancing autophagy and dampening NLRP3-mediated inflammation, offering a promising therapeutic avenue.
anti-psoriasis drugs / autophagy / GS-9620 / NLRP3 / PASI / psoriasis
| [1] |
|
| [2] |
|
| [3] |
|
| [4] |
|
| [5] |
|
| [6] |
|
| [7] |
|
| [8] |
|
| [9] |
|
| [10] |
|
| [11] |
|
| [12] |
|
| [13] |
|
| [14] |
|
| [15] |
|
| [16] |
|
| [17] |
|
| [18] |
|
| [19] |
|
| [20] |
|
| [21] |
|
| [22] |
|
| [23] |
|
| [24] |
|
| [25] |
|
| [26] |
|
| [27] |
|
| [28] |
|
| [29] |
|
| [30] |
|
2026 The Author(s). Animal Models and Experimental Medicine published by John Wiley & Sons Australia, Ltd on behalf of The Chinese Association for Laboratory Animal Sciences.
/
| 〈 |
|
〉 |